A Phase 1 interventional study of ADVM-022 in Wet Age-related Macular Degeneration and Neovascular Age-related Macular Degeneration, sponsored by Adverum Biotechnologies, Inc.. Completed at 11 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-08-08.
Sponsored by Adverum Biotechnologies, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Blindness with a site in United States — 14 open to participants now, 24 under way, 4 of them phase 3. Blindness · United States.
Among the 77 studies in Blindness with a site in United States, this one is the 28th largest by enrollment of the 62 interventional ones that give a count, is one of 4 that started in 2018, is one of 3 in phase 1, and was the 48th registered.
144 studies on the registry are indexed under Blindness; 33 are open to participants now.
Browse Blindness studies →14 of the 77 studies in Blindness with a site in United States are open now. Recruiting first, the newest first:
Adverum Biotechnologies, Inc. · Sites in United States
Ages 50+
Adverum Biotechnologies, Inc. · Sites in United States
Ages 50+
The Chicago Lighthouse · Sites in United States
Ages 18+
Laboratoires Thea · Sites in United States, Australia, Belgium and 7 more countries
Ages 6+
University of Rochester · Sites in United States
Ages 21–80 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Blindness studies recruiting now, 13 (65%) set no upper age limit and 4 (20%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 9 · Phase 4 2
First in 1994; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 37 across 101 interventional studies indexed under Blindness.
Median enrollment 28 across the 62 interventional studies, 35 across the 15 observational. Of the 47 that completed or were terminated, 25 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 77 have an industry lead sponsor. The 10 most frequent:
This study is registered under Adverum Biotechnologies, Inc., one of the names counted as Eli Lilly and Company. Under that name alone:
Adverum Biotechnologies, Inc. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Eli Lilly and Company has 8 studies filed under Blindness — fewer than ten, so there is no comparison to draw.
8 of the studies in Blindness with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06856577Phase 3Adverum Biotechnologies, Inc.Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration | 2026-12-22 |
| NCT06891443Phase 3Laboratoires TheaStudy to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) | 2027-11 |
| NCT07482176Phase 3Adverum Biotechnologies, Inc.Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) | 2027-11-15 |
| NCT02747589University of California, Los AngelesFeasibility of Stimulating the Visual Cortex in Blind | 2026-12-31 |
| NCT04634383Illinois Institute of TechnologyA Phase I Feasibility Study of an Intracortical Visual Prosthesis (ICVP) for People With Blindness | 2027-06-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 77 studies in Blindness with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product developed for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is a serious condition and the leading cause of blindness in the elderly. The available therapies for treating wet AMD require life-long intravitreal (IVT) injections every 4-12 weeks to maintain efficacy. A one-time IVT administration of ADVM-022 has the potential to treat wet AMD by providing durable expression of therapeutic levels of intraocular anti-VEGF protein (aflibercept) and maintaining the vision of patients. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with wet AMD receiving anti-VEGF therapy in clinical practice.
This open-label, multicenter, dose-ranging study will evaluate 2 dose levels in up to 30 subjects (15 per dose) with active choroidal neovascularization (CNV) secondary to AMD. Subjects who are under active anti-VEGF treatment and have demonstrated a meaningful response to anti-VEGF therapy will be considered for participation in this study. The primary endpoint for this study is safety and tolerability of ADVM-022. All subjects will continue to be assessed for 104 weeks following treatment with ADVM-022.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6E11 vg of ADVM-022
Biological: ADVM-022
2E11 vg of ADVM-022
Biological: ADVM-022
ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
Also known as: AAV.7m8-aflibercept
Type, severity, and incidence of ocular and systemic adverse events (AEs)
Type, severity, and incidence of ocular and systemic adverse events (AEs)
Time frame: 104 weeks
Change in best corrected visual acuity (BCVA)
Change in best corrected visual acuity (BCVA)
Time frame: 104 weeks
Change in central subfield thickness (CST) and macular volume measured by SD-OCT
Change in central subfield thickness (CST) and macular volume measured by SD-OCT
Time frame: 104 weeks
Percentage of subjects requiring anti-VEGF injections over time
Percentage of subjects requiring anti-VEGF injections over time
Time frame: 104 weeks
Mean number of anti-VEGF injections over time
Mean number of anti-VEGF injections over time
Time frame: 104 weeks
Percentage of subjects without intraretinal fluid over time
Percentage of subjects without intraretinal fluid over time
Time frame: 104 weeks
Percentage of subjects without subretinal fluid over time
Percentage of subjects without subretinal fluid over time
Time frame: 104 weeks
Ran from Nov 2018 to primary completion in Jun 2022, 43 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adverum Biotechnologies, Inc. →